Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight loss results comparable to those of popular GLP-1 injectables like ...

Fact checked by Nick BlackmerFact checked by Nick Blackmer In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months. Amycretin ...

The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...

The new results with a once-weekly subcutaneous injection of amycretin – which is also being developed in a daily oral formulation – show that the combined GLP-1 and amylin agonist achieved up ...